GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

PROF · Mar 31, 2026

Profound Medical Corp.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001104659-26-057198General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

84.37% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-160.82% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

127.98% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

168.65% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

71.80% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-150.29% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

98.59% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

19.64% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History7 statesHistory building

Dec 31, 20240/7 normalizedLevel 3 Mar 31, 20250/7 normalizedLevel 3 Jun 30, 20250/7 normalizedLevel 3 Sep 30, 20250/7 normalizedLevel 3 Dec 31, 20250/9 normalizedLevel 3 Mar 31, 20260/8 normalizedLevel 3 Jun 30, 20260/8 normalizedLevel 3

Period transition

What moved in the state?

Balance Sheet Leverage Increased

Previous: 27.95%
Current: 84.37%
Delta: 56.43%

Cash Generation Increased

Previous: -237.34%
Current: -160.82%
Delta: 76.52%

Growth Increased

Previous: 65.28%
Current: 127.98%
Delta: 62.70%

Inventory Pressure Increased

Previous: 51.17%
Current: 168.65%
Delta: 117.48%

Margin Increased

Previous: 70.77%
Current: 71.80%
Delta: 1.03%

Profitability Increased

Previous: -256.27%
Current: -150.29%
Delta: 105.98%

R And D Intensity Decreased

Previous: 127.94%
Current: 98.59%
Delta: -29.35%

Sbc Intensity Decreased

Previous: 34.10%
Current: 19.64%
Delta: -14.47%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Has State · Profound Medical Corp. →Transitioned To · PROF Fundamental State →Transitioned To · PROF BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · PROF CASH_GENERATION_INCREASED →Transitioned To · PROF GROWTH_INCREASED →Transitioned To · PROF INVENTORY_PRESSURE_INCREASED →Transitioned To · PROF MARGIN_INCREASED →Transitioned To · PROF PROFITABILITY_INCREASED →Transitioned To · PROF R_AND_D_INTENSITY_DECREASED →Transitioned To · PROF SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.